文献速递乳腺癌消化系统肿瘤

精简拉美乳腺癌与结直肠癌生物类似药监管以改善治疗可及性:专家小组视角

Streamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment access in Latin America: an expert panel perspective.
PubMed 文献 · Lancet Oncol · 2022-01-01

多日会议中,拉美生物制剂肿瘤治疗与卫生经济学专家小组围绕乳腺癌和结直肠癌患者生物类似药可及性障碍展开讨论,经讨论与修改达成共识。会议识别出监管异质性、不遵循监管路径、市场机会稀缺、仅用国际非专利名命名、互换性与替代概念使用不精确、可追溯性与药物警戒不足等挑战,并提出改进监管路径实施与可靠采购策略的建议。

要点

  • 专家小组共识指出,拉美生物类似药监管存在异质性、不遵循监管路径、市场机会稀缺等障碍。
  • 命名仅用国际非专利名、互换性与替代概念使用不精确被视为监管挑战。
  • 建议改进监管路径实施与可靠采购策略,以提升可追溯性与结局测量下的治疗可及性。

核心结论

  • 专家小组提出建议,可作为其他处于类似情况国家采用生物类似药的策略。
  • 所有相关利益方的努力将至关重要。

研究设计与样本

  • 多日会议中,由拉丁美洲生物制剂肿瘤治疗与卫生经济学专家组成的小组就限制生物类似药可及性的问题接受提问。
  • 会议期间对回答进行讨论和编辑,直至达成共识。

主要发现

  • 会议识别的监管挑战包括监管异质性、不遵循监管路径、市场机会稀缺。
  • 监管挑战还包括仅使用国际非专利名命名生物类似药、互换性与替代概念使用不精确。
  • 监管挑战还包括可追溯性与药物警戒不足。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In a multiday conference, a panel of Latin American experts in biological cancer therapies and health economics were provided with questions to address the barriers restricting access to biosimilars in Latin America, specifically for patients with breast cancer and colorectal cancer, for whom biosimilars can be a path forward to increasing access to care. During the conference, responses were discussed and edited until a consensus was achieved. The regulatory challenges identified in the conference included heterogenous regulations, non-adherence to regulatory pathways, scarcity of market opportunity, inadequate naming of biosimilars by only using international non-proprietary names, imprecise use of interchangeability and substitution, and insufficient traceability and pharmacovigilance. Recommendations were developed to improve the implementation of regulatory pathways and reliable procurement strategies that increase access to these therapies with adequate traceability and outcome measures; efforts from all involved stakeholders will be crucial. These recommendations can serve as a strategy for biosimilar adoption in other countries in a similar situation.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Teran E, Gomez H, Hannois D, et al. Streamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment access in Latin America: an expert panel perspective. Lancet Oncol. 2022. PMID: 35772466. doi:10.1016/S1470-2045(22)00121-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。